Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro
- PMID: 1738367
- DOI: 10.1210/mend.6.1.1738367
Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro
Abstract
We found previously that transforming growth factor-beta 1 (TGF beta 1) mRNA levels are markedly elevated in rat prostate cancer (Dunning R3327 sublines) compared to levels in normal prostate. Our goal was to determine whether elevated expression of TGF beta 1 is biologically relevant to prostate cancer growth in vivo. We chose as our model the R3327-MATLyLu prostate cancer epithelial cell line, which produces metastatic anaplastic tumors when reinoculated in vivo. Our approach was to stably transfect MATLyLu cells with an expression vector that codes for latent TGF beta 1 and to isolate subclones of cells that over-expressed TGF beta 1 mRNA. We also isolated a subclone of MATLyLu cells transfected with a control vector lacking the TGF beta 1 cDNA insert. We then studied the growth of these cells in vivo and in vitro. Twenty days after sc inoculation of 10(6) cells in vivo, TGF beta 1-overproducing MATLyLu tumors were 50% larger, markedly less necrotic, and produced more extensive metastatic disease (lung metastases in 73% of all lobes and lymph node metastases in 88% of animals) compared to control MATLyLu tumors (lung metastases, 21%; lymph node metastases, 7%). Thus, TGF beta 1 produced in vivo is biologically active and can promote prostate cancer growth, viability, and aggressiveness, perhaps via effects on the host and/or on the tumor cells themselves. When followed in vitro, TGF beta 1-overproducing cells became growth inhibited, but this effect was transient as cells subsequently resumed proliferating. Growth inhibition was due to TGF beta, because it could be prevented by TGF beta-neutralizing antibody. Therefore, prostate cancer cells can activate and respond to secreted latent TGF beta 1, and although the cells are transiently inhibited in vitro, there is no net inhibition of growth. The ability of the cells to respond to endogenously produced TGF beta 1 suggests that TGF beta 1 overexpression enhances tumor growth in vivo at least in part via an effect of TGF beta 1 on the tumor cells themselves.
Similar articles
-
Expression of transforming growth factor-beta 1 in prostate cancer.Endocrinology. 1994 Nov;135(5):2240-7. doi: 10.1210/endo.135.5.7956947. Endocrinology. 1994. PMID: 7956947
-
Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.Clin Cancer Res. 2005 Jun 15;11(12):4512-20. doi: 10.1158/1078-0432.CCR-04-2571. Clin Cancer Res. 2005. PMID: 15958637
-
Effects of transforming growth factor beta 1 on the adenylyl cyclase-cAMP pathway in prostate cancer.Growth Factors. 1994;11(4):283-90. doi: 10.3109/08977199409011001. Growth Factors. 1994. PMID: 7779408
-
TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity.Prostate. 1997 Apr 1;31(1):61-70. doi: 10.1002/(sici)1097-0045(19970401)31:1<61::aid-pros10>3.0.co;2-m. Prostate. 1997. PMID: 9108888 Review.
-
Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer.Anticancer Drugs. 2005 Nov;16(10):1045-51. doi: 10.1097/00001813-200511000-00002. Anticancer Drugs. 2005. PMID: 16222145 Review.
Cited by
-
Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.J Clin Invest. 1993 Dec;92(6):2569-76. doi: 10.1172/JCI116871. J Clin Invest. 1993. PMID: 7504687 Free PMC article.
-
TGF beta-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein.Mol Biol Cell. 1996 Sep;7(9):1335-42. doi: 10.1091/mbc.7.9.1335. Mol Biol Cell. 1996. PMID: 8885230 Free PMC article.
-
Molecular biology of prostate cancer.World J Urol. 1996;14(5):318-28. doi: 10.1007/BF00184605. World J Urol. 1996. PMID: 8912472 Review.
-
"Stromal cells in prostate cancer pathobiology: friends or foes?".Br J Cancer. 2023 Apr;128(6):930-939. doi: 10.1038/s41416-022-02085-x. Epub 2022 Dec 8. Br J Cancer. 2023. PMID: 36482187 Free PMC article. Review.
-
Restoration of Smad4 in BxPC3 pancreatic cancer cells attenuates proliferation without altering angiogenesis.Clin Exp Metastasis. 2005;22(6):461-73. doi: 10.1007/s10585-005-2891-x. Clin Exp Metastasis. 2005. PMID: 16320109
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical